



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 June 2013
EMA/PDCO/296162/2013
Human Medicines Development and Evaluation

Paediatric Committee (PDCO)

Draft minutes of the 15-17 May 2013 meeting

Chair: Daniel Brasseur

I Introduction

I.1 Adoption of the minutes from previous meeting

Adopted

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

Adopted with modifications

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex 1.

I.4 External attendance

Please refer to the May 2013 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the May 2013 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab



II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the May 2013 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed 82 procedures in total¹, of which:

- 38 paediatric investigation plan applications;
- 13 product-specific waiver applications;
- 5 compliance check procedures (interim and final);
- 26 requests for modifications of an agreed paediatric investigation plan.

IV Nomination of Rapporteurs and Peer reviewers

<ul style="list-style-type: none">• List of letters of intent received for submission of applications with start of procedure July 2013 ¹for Nomination of Rapporteur and Peer reviewer• Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.
---	--

V Update and finalisation of opinions and requests for modification

All opinions taken at this meeting (relating to adoption of opinions, recommendations, requests for modifications and applicability of class waivers) were made in the presence of the required quorum of members.

The opinions adopted during the Paediatric Committee meeting of May 2013 are published in the same month's meeting report published in the EMA website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

¹ The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the [PDCO Committee meeting reports](#) (after the PDCO Opinion is adopted), and on the [Opinions and decisions on paediatric investigation plans webpage](#) (after the EMA Decision is issued).

VI Discussion on the applicability of class waiver

Class waiver number	Active substance	Proposed indication	Condition	Outcome
EMA-18-2013	Alpha-1 antitrypsin (AAT)	Treatment of individuals with congenital deficiency of alpha-1-proteinase inhibitor (API) with clinically demonstrable panacinar emphysema	Treatment of chronic obstructive pulmonary disease (COPD)	Not confirmed
EMA-19-2013	RO5509554, RG7155, CSF-1R	Treatment of breast carcinoma	Treatment of breast carcinoma	Confirmed
EMA-20-2013	RO5509554, RG7155, CSF-1R	Treatment of ovarian carcinoma	Treatment of ovarian carcinoma	Confirmed
EMA-21-2013	Ganetespib	Ganetespib is indicated in combination with docetaxel for the treatment of patients with locally advanced or metastatic non-small cell adenocarcinoma of the lung after failure of prior platinum-based chemotherapy or other therapy for advanced disease	Non-small cell lung carcinoma	Confirmed

VII Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

PIP number	Active substance	Proposed indication	Condition	Outcome
EMA-000699-PIP01-09	linagliptin (base)/metformin (hydrochloride)	In combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin and meformin alone do not provide	Diabetes type 2	Inclusion confirmed.

		adequate glycaemic control.		
--	--	-----------------------------	--	--

VIII Annual reports on deferrals

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan drug	Difficulties progressing the PIP?	Outcome
EMA-001167-PIP02-11	Atomoxetine hydrochloride	Strattera	No	Yes No	Postponed to June PDCO
EMA-000183-PIP01-08	Apixaban	Eliquis	No	Yes No	Postponed to June PDCO
EMA-000183-PIP02-12	apixaban	Eliquis	No	Yes No	Postponed to June PDCO
EMA-000365-PIP01-08	Oseltamivir phosphate	Tamiflu®	No	No Yes	Postponed to June PDCO
EMA-000118-PIP02-10	Abatacept	ORENCIA	No	TBC	Postponed to June PDCO
EMA-000470-PIP01-08	Sitagliptin phosphate monohydrate	Januvia	No	Yes No	Postponed to June PDCO
EMA-000713-PIP02-10	pixantrone dimaleate	Pixuvri	Yes	Yes No	Postponed to June PDCO
EMA-000429-PIP01-08	N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid	Nimenrix	No	No Yes	Postponed to June PDCO
EMA-000065-PIP01-07	telbivudine	Sebivo	No	Yes No	Postponed to June PDCO
EMA-000116-PIP01-07	Retigabine	Trobalt	No	Yes No	Postponed to June PDCO

IX Other topics

Guidelines	
Guideline on clinical investigation of medicinal	PDCP endorsed the draft guideline and agreed with

products for the treatment of juvenile idiopathic arthritis	its publication for public consultation.
Guideline on clinical investigation of medicinal products in the treatment of depression	Document tabled for information; the PDCO had no further comments regarding the latest changes in the section on 'augmentation/add-on therapy in partial responders'.
Working groups	
Paediatric oncology	The group discussed forthcoming meetings with stakeholders and recent scientific developments
Paediatric inventory	The working group discussed the therapeutic areas nephro-urology and neurology.
Extrapolation	The working group discussed 2 product specific PIPs with extrapolation issues
Formulation	No non-product related issues were reported to the Committee.
Non-Clinical	Documents tabled for information
Other topics	
PRAC List of outstanding issues to be addressed by the marketing authorisation holder(s) for codeine containing medicinal products used for pain in children	<ul style="list-style-type: none"> • The PDCO consider the use of codeine as any analgesic in different paediatric age groups. Concerns regarding the restriction of its use were expressed due to the lack of alternative analgesics across Member States (MSs) • The increased risk of morphine intoxication due to genetic polymorphism of its metabolic pathway was taken into consideration balanced against a limited analgesic benefit compared to other simple analgesics (i.e. paracetamol and ibuprofen). However it was acknowledged that there is a significant lack of robust data investigating the use of codeine in the paediatric population • It was recognised that the use of codeine in the paediatric population varies significantly in the paediatric clinical practice among MSs • The PDCO agreed with the contraindication of the use of codeine in all paediatric patients (0 to 18 years of age) that undergo tonsillectomy and/or adenoidectomy for Obstructive Sleep Apnoea Syndrome due to an increased risk of respiratory depression • - It was agreed that the risk of codeine's genetic polymorphism should be communicated to the healthcare professionals across EU.

HMPC Monographs: Overview of recommendations for the use of herbal medicinal products in the paediatric population	<p>"HMPC Monographs" was presented by Silvia Girotto to PDCO members. This document provides an overview of recommendations for use of herbal preparation in paediatric population:</p> <ul style="list-style-type: none"> • The document was adopted by HMPC on 15/05/13 and is going to be published on EMA, herbal medicinal products webpages (date TBC) • The document will be sent to all PDCO members along in the PDCO post mail. PDCO members are invited to comment on this document • HMPC monographs are revised every 5 years but Silvia Girotto does updates every 6 months so comments from PDCO members if any are welcome by 15/11/13
Other topics	
<p>Mandate, objectives and rules of procedure for the European Medicines Agency Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP)*</p> <p>Mandate, objectives and rules of procedure for the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP)*</p>	This document was presented to the Committee for information.
Draft agenda PCWP/ HCPWP joint meeting 5 June 2013*	This document was presented to the Committee for information.
Draft Agenda - PCWP meeting 6 June 2013*	This document was presented to the Committee for information.
Draft agenda of the HCPWP meeting on 5 June 2013*	This document was presented to the Committee for information.
Nomination of the CHMP representatives in the HCPWP	This document was presented to the Committee for information.
Update on Enpr-EMA activities	The annual 2-day meeting of Enpr-EMA which will take place on 27 and 28 June at the EMA was announced.
<p>Update on H7N9 influenza activities</p> <p>Revision of standard PIP</p>	Ragini Shivji updated the PDCO on the current preparedness activities for H7N9 influenza and Sophie Olivier presented a first draft revision of standard PIP for pandemic influenza vaccines. Document tabled for comments by next PDCO meeting.

Summary of Opinion template and guidance*	Postponed to June PDCO.
Reflection on class waiver revocation	The PDCO continued the review of the class waivers
CHMP update on paediatric topics	The PDCO members were informed about the final CHMP opinions on medicinal products with paediatric interest adopted in May 2013.
"PDCO news" at CHMP	The PDCO was informed that a timeslot has been reserved in the Agenda of each CHMP meeting, for the presentation of items of interest from the PDCO activities. The first session will be in the May CHMP.
Proposals for topics for a suggested common informal meeting of PDCO SAWP in November 2013.	Call for proposals by next PDCO meeting. Please send your proposals to the PDCO secretariat.
PIPs with long deferrals	A short presentation [#] on PIPs with long deferrals (completion more than 6 years after planned date of marketing authorisation application) was given to the DCO
Paediatric addendum* to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension	Adopted by the PDCO.
Role and organisation of future informal PDCO meetings	Discussion postponed to June meeting.

Any other business

N/A

Note on access to documents

Documents marked with an asterisk* in these minutes cannot be released at present as they are currently in draft format. They will become public when adopted in their final form. Documents marked with [#] contain commercially confidential information and cannot be released.

Annex I to the Minutes of the PDCO of May 2013

Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

Member, alternate, expert name	Outcome restriction following evaluation of electronic Declaration of Interests	Topics on the current Committee Agenda for which this restriction applies
Adriana Ceci	Restriction level DP	EMEA-001039-PIP02-12
Adriana Ceci	Restriction level DP	EMEA-001366-PIP01-12
Adriana Ceci	Restriction level DP	EMEA-000366-PIP02-09-M02
Alexandra Compagnucci	Restriction level XR	EMEA-001464-PIP01-13
Carine de Beaufort	Restriction level XR	EMEA-001441-PIP01-13
Carine de Beaufort	Restriction level XR	EMEA-001464-PIP01-13
Carine de Beaufort	Restriction level XR	EMEA-000430-PIP01-08-M04
Christoph Male	Restriction level XP	EMEA-000480-PIP01-08-M05
Christoph Male	Restriction level XP	EMEA-000430-PIP01-08-M04
Dobrin Konstantinov	Restriction level XP	EMEA-001301-PIP01-12
Dobrin Konstantinov	Restriction level DP	EMEA-000469-PIP01-08-M04
Gerard Pons	Restriction level DP	EMEA-000467-PIP01-08-M03
Jaroslav Sterba	Restriction level XP	EMEA-000227-PIP02-12
Jaroslav Sterba	Restriction level XP	EMEA-001397-PIP01-12
Jaroslav Sterba	Restriction level XP	EMEA-000469-PIP01-08-M04
Jean-Pierre Aboulker	Restriction level XR	EMEA-001464-PIP01-13
Matthias Keller	Restriction level DP	EMEA-001305-PIP01-12
Matthias Keller	Restriction level XR	EMEA-000366-PIP02-09-M02
Michal Odermarsky	Restriction level XP	EMEA-000222-PIP01-08-M07
Paolo Rossi	Restriction level XR	EMEA-000469-PIP01-08-M04

Member, alternate, expert name	Outcome restriction following evaluation of electronic Declaration of Interests	Topics on the current Committee Agenda for which this restriction applies
Paolo Rossi	Restriction level XR	EMEA-001430-PIP01-13
Paolo Rossi	Restriction level XR	EMEA-001441-PIP01-13
Paolo Rossi	Restriction level XR	EMEA-000576-PIP03-12
Paolo Rossi	Restriction level DP	EMEA-000830-PIP02-10-M01
Tadej Avcin	Restriction level XP	EMEA-000366-PIP02-09-M02

Note: the procedures identified in the table above are on-going and therefore considered commercially confidential. Additional details on these procedures will be disclosed in the [PDCO Committee meeting reports](#) (after the PDCO Opinion is adopted), and on the [Opinions and decisions on paediatric investigation plans webpage](#) (after the EMA Decision is issued).

No new or additional conflicts were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Restriction levels:

Evaluation of the conflict of interest	
Outcome	Impact
R-P	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.
XP	Where Individual product involvement is declared - PRODUCT INDICATION: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products - [Cannot act as Rapporteur for development of guidelines in concerned therapeutic area].
XC	Where cross product / general involvement is declared - COMPANY: - No involvement (as outlined above) with respect to products from the specified company. - Cannot act as Rapporteur for products from the relevant company(ies).
DP	Where Individual product involvement is declared - PRODUCT INDICATION: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product i.e. no part in final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products.

DC	Where cross product / general involvement is declared - COMPANY: - Involvement in discussions only with respect to products from the specified company. - Cannot act as Rapporteur on products from the relevant company(ies).
XR	Committee member cannot act as Rapporteur or Peer reviewer in relation to any medicinal product from the relevant company.
R-C	To be replaced for the discussions, final deliberations and voting as appropriate in relation to any medicinal product from the relevant company

Annex II to the Minutes of the PDCO of May 2013

List of Participants

Chair

Daniel BRASSEUR

Vice-chair

Dirk MENTZER

Members appointed by Member States or CHMP

Christoph MALE	Austria
Koenraad NORGA	Belgium
Dobrin KONSTANTINOV	Bulgaria
George SAVVA	Cyprus
Jaroslav STERBA	Czech Republic
Marianne ORHOLM	Denmark
Irja LUTSAR	Estonia
Pirjo LAITINEN-PARKONNEN	Finland
Gerard PONS	France
Dirk MENTZER	Germany
Agnes GYURASICS	Hungary
Gylfi OSKARSSON	Iceland
Kevin CONNOLLY	Ireland
Paolo ROSSI	Italy
Carine de BEAUFORT	Luxembourg
Hendrik van den BERG	The Netherlands
Siri WANG	Norway
Marek MIGDAL	Poland
Helena FONSECA	Portugal
Fernando DE ANDRÉS TRELLES	Spain
Marta GRANSTRÖM	Sweden
Julia DUNNE	United Kingdom

Alternates appointed by Member States or CHMP

Karl Heinz HUEMER	Austria
Jacqueline CARLEER	Belgium
Ann Marie KAUKONEN	Finland
Sylvie BENCHETRIT	France
Birka LEHMANN	Germany
Francesca ROCCHI	Italy
Herbert LENICKER	Malta
Johannes TAMINIAU	The Netherlands
Jolanda WITKOWSKA-OZOGOWSKA	Poland
Hugo TAVARES	Portugal
Dana Gabriela MARIN	Romania
Maria Jesus FERNANDEZ CORTIZO	Spain
Viveca Lena ODLIND	Sweden
Angeliki SIAPKARA	United Kingdom

Members representing patients'

Michal ODERMARSKY

Members representing health care professionals

Anthony James NUNN

Alternates representing health care professionals

Paolo PAOLUCCI

Experts

Peter BAUER	Medical statistician
Christina PETERS	European Group for Blood and Marrow Transplantations
Anna Afentaki	Bundesinstitut für Arzneimittel und Medizinprodukte

European Medicines Agency

Agnes SAINT RAYMOND	Head of Sector, Human Medicines Special Areas
Paolo TOMASI	Head of Section, Paediatric Medicines
Sophie OLIVIER	Scientific Administrator, Paediatric Medicines
Anne-Sophie HENRY-EUDE	Scientific Administrator, Paediatric Medicines
Almudena SAIZ HERRANZ	Scientific Administrator, Paediatric Medicines

Benjamin PELLE	Scientific Administrator, Paediatric Medicines
Chrissi PALLIDIS	Scientific Administrator, Paediatric Medicines
Dobromir PENKOV	Scientific Administrator, Paediatric Medicines
Elin Haf DAVIES	Scientific Administrator, Paediatric Medicines
Emilie DESFONTAINE	Scientific Administrator, Paediatric Medicines
Giovanni LESA	Scientific Administrator, Paediatric Medicines
Gunter EGGER	Scientific Administrator, Paediatric Medicines
Irmgard EICHLER	Scientific Administrator, Paediatric Medicines
Janina KARRES	Scientific Administrator, Paediatric Medicines
Peter KÁROLYI	Scientific Administrator, Paediatric Medicines
Ralf HEROLD	Scientific Administrator, Paediatric Medicines
Ralph BAX	Scientific Administrator, Paediatric Medicines
Richard VESELY	Scientific Administrator, Paediatric Medicines
Thorsten OLSKI	Scientific Administrator, Paediatric Medicines
Alessandro JENKNER	National Expert on Secondment, Paediatric Medicines
Cristina BEJNARIU	Trainee
Aurelie HERVIEU	Assistant, Paediatric Medicines
Aneta KRZYSCIAK	Assistant, Paediatric Medicines
Sunni HOLTMAN	Assistant, Paediatric Medicines